CartiHeal
Kfar Saba
About CartiHeal
CartiHeal, a privately held medical device company headquartered in Israel, is a pioneer in the field of cartilage regeneration. Cartilage injuries affect millions of patients around the world, and characteristically cause severe pain and disability. Hyaline cartilage has a very limited ability to heal once damaged. Research indicates that injuries to joint cartilage, if left untreated, may lead to progressive joint changes and early onset of osteoarthritis. The need for a simple, well-tolerated and effective solution for cartilage repair and regeneration represents one of medicine’s most challenging unmet needs. CartiHeal's flagship Agili-C™ implant represents a significant medical breakthrough. This implant has shown to promote regeneration of true hyaline cartilage and its subchondral bone, simultaneously without the use of cells, growth factors or other exogenous agents. The cell-free implant is inserted arthroscopically or via a minimally-invasive approach.
Company Facts
- Operating status: Closed
- Company type: For Profit
- IPO status: Private
- Employees: 501 – 1,000
- Estimated revenue: $10K – $50K
- Total funding: $41.5M
- Funding stage: M&A
- Last round: Corporate Round (Jul 2020)
- Website: cartiheal.com
- Phone: 972 9 881 0400
Industries & Categories
Health Care, Manufacturing, Medical Device
Social Profiles
Canonical: https://fsome.com/organization/cartiheal-137675 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.